Compare Eli Lilly And Co (LLY) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Oklo Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Oklo Inc trades at $34.7 (market cap $6.43B). The key difference: Eli Lilly And Co is far larger — about 161.7× Oklo Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Oklo Inc for 32 Days on average.
| LLY | OKLO | |
|---|---|---|
Market Cap | $1.04T | $6.43B |
Volume | 3,064,878 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $1.28K | $174.14 |
52-Week Low | $799.57 | $34.57 |
Typical Hold Time | 93 Days | 32 Days |
Enterprise Value | $1.09T | $3.97B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
OKLO trades at $34.57, down 6.11% with bearish technical signals despite strong analyst support. The company shows no revenue in 2025 with significant losses (-$105.66M net income) and negative margins, though cash flow from financing provides runway. Recent news highlights nuclear sector volatility and OKLO's $1 billion stock sale raising dilution concerns.
Outlook hinges on project execution amid high risk-reward dynamics. Analyst consensus is bullish (71% Buy) with a $78.63 price target, but profitability challenges and cash burn pose substantial risks. Success depends on commercializing its nuclear reactor pipeline to capitalize on the growing AI power demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
